Postpartum Depression

Sorry, no news articles match your request. Your search criteria may be too narrow.

Postpartum depression (PPD), also called postnatal depression, is a form of clinical depression which can affect women, and less frequently men, typically after childbirth. Studies report prevalence rates among women from 5% to 25%, but methodological differences among the studies make the actual prevalence rate unclear. Among men, in particular new fathers, the incidence of postpartum depression has been estimated to be between 1.2% and 25.5%. Postpartum depression occurs in women after they have carried a child, usually in the first few months, and may last up to several months or even a year. Specifically, the onset of postpartum depression begins within 4 weeks and lasting up to 6 months after giving birth. Symptoms include sadness, fatigue, changes in sleeping and eating patterns, reduced libido, crying episodes, anxiety, and irritability. Although a number of risk factors have been identified, the causes of PPD are not well understood. Many women recover with a treatment consisting of a support group or counseling.

The Edinburgh Postnatal Depression Scale, a standardized self-reported questionnaire, may be used to identify women who have postpartum depression.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

At last, hope for ALS patients?

U of T researchers have found a missing link that helps to explain how ALS, one of the world's most feared diseases, paralyses and ultimately kills its victims. The breakthrough is helping them trace a path to a treatment ...

Stem cells from nerves form teeth

Researchers at Karolinska Institutet in Sweden have discovered that stem cells inside the soft tissues of the tooth come from an unexpected source, namely nerves. These findings are now being published in the journal Nature and co ...

$1,000 pill now hepatitis C treatment of choice

(AP)—A $1,000-per-pill drug that insurers are reluctant to pay for has quickly become the treatment of choice for a liver-wasting viral disease that affects more than 3 million Americans.